Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 5/2012

01-10-2012 | Lymphomas (PA Hamlin, Section Editor)

Transformation in Follicular Lymphoma: Biology, Prognosis, and Therapeutic Options

Authors: Eric Wong, Michael Dickinson

Published in: Current Oncology Reports | Issue 5/2012

Login to get access

Abstract

The transformation of follicular lymphoma to an aggressive lymphoma is a well-recognised complication that occurs at a rate of approximately 3 % a year for the first 10 years of observation. Transformation is accompanied by increased risk of refractoriness and a poor expectation of survival. Genetic and epigenetic triggers for transformation have been described. Prior to routine use of rituximab, transformed lymphoma was managed in a fashion similar to that for de novo diffuse large B-cell lymphoma, with generally poor results. Rituximab appears to have improved outcomes. Some centres, including our own, use high-dose chemotherapy with stem cell transplantation as consolidation for those with responsive disease. Here, we focus on transformed follicular lymphoma, and provide an overview of the current literature and our approach to management.
Literature
1.
Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311(23):1471–5.PubMedCrossRef
2.
Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(32):5165–9.PubMedCrossRef
3.
Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15(4):1587–94.PubMed
4.
Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PMV, Stathis A et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol. 2012;157(2):188-96.
5.
Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17):2426–33.PubMedCrossRef
6.
Garvin AJ, Simon RM, Osborne CK, Merrill J, Young RC, Berard CW. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer. 1983;52(3):393–8.PubMedCrossRef
7.
Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(21):4643–51.PubMedCrossRef
8.
Bodet-Milin C, Kraeber-Bodéré F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica. 2008;93(3):471–2.PubMedCrossRef
9.
• Noy A, Schöder H, Gönen M, Weissler M, Ertelt K, Cohler C et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20(3):508-12. Described the utility of standardised uptake values in identifying transformed lymphoma. PubMedCrossRef
10.
Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol. 2006;17(10):1539–45.PubMedCrossRef
11.
Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–22.PubMedCrossRef
12.
Sinha R, Byrtek M, De Joubner N, Nooka A, Taylor M, Cerhan J, et al. Examining the outcomes of watchful waiting among US patients with advanced stage follicular lymphoma [abstract 775]. American Society of Haematology Conference 2011.
13.
Cohen Y, Da'as N, Libster D, Amir G, Berrebi A, Polliack A. Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication? Eur J Haematol. 2002;68(2):80–3.PubMedCrossRef
14.
Matolcsy A, Schattner EJ, Knowles DM, Casali P. Clonal evolution of B cells in transformation from low- to high-grade lymphoma. Eur J Immunol. 1999;29(4):1253–64.PubMedCrossRef
15.
Rossi D, Berra E, Cerri M, Deambrogi C, Barbieri C, Franceschetti S, et al. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. Haematologica. 2006;91(10):1405–9.PubMed
16.
Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol. 2007;136(2):286–93.PubMedCrossRef
17.
Gentles AJ, Alizadeh AA, Lee S-I, Myklebust JH, Shachaf CM, Shahbaba B, et al. A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood. 2009;114(15):3158–66.PubMedCrossRef
18.
Symmans WF, Katz RL, Ordoñez NG, Dalton H, Romaguera JE, Cabanillas F. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Acta Cytol. 1995;39(4):673–82.PubMed
19.
Szereday Z, Csernus B, Nagy M, László T, Warnke RA, Matolcsy A. Somatic mutation of the 5' noncoding region of the BCL-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma. Am J Pathol. 2000;156(3):1017–24.PubMedCrossRef
20.
Carlotti E, Wrench D, Matthews J, Iqbal S, Davies A, Norton A, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood. 2009;113(15):3553–7.PubMedCrossRef
21.
Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood. 2010;116(9):1489–97.PubMedCrossRef
22.
Martinez A, Carreras J, Campo E. The follicular lymphoma microenvironment: from tumor cell to host immunity. Curr Hematol Malignancy Rep. 2008;3(4):179–86.CrossRef
23.
Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007;25(4):390–8.PubMedCrossRef
24.
Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108(9):2957–64.PubMedCrossRef
25.
Skibola CF, Bracci PM, Halperin E, Conde L, Craig DW, Agana L, et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet. 2009;41(8):873–5.PubMedCrossRef
26.
Akers NK, Curry JD, Conde L, Bracci PM, Smith MT, Skibola CF. Association of HLA-DQB1 alleles with risk of follicular lymphoma. Leuk Lymphoma. 2011;52(1):53–8.PubMedCrossRef
27.
Wrench D, Leighton P, Skibola CF, Conde L, Cazier J-B, Matthews J, et al. SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood. 2011;117(11):3147–50.PubMedCrossRef
28.
Al-Tourah AJ, Savage KJ, Gill KK, Klasa RJ, Sehn LH, Shenkier TN, et al. Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. ASH Annu Meet Abstr. 2007;110(11):790.
29.
Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(12):3793–803.PubMed
30.
Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14(7):1974–81.PubMed
31.
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20(10):2453–63.PubMedCrossRef
32.
Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19(19):3918–28.PubMed
33.
Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J Clin Oncol. 2005;23(30):7565–73.PubMedCrossRef
34.
Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, et al. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant. 2005;36(11):955–61.PubMedCrossRef
35.
Chen CI, Crump M, Tsang R, Stewart AK, Keating A. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol. 2001;113(1):202–8.PubMedCrossRef
36.
•• Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M et al. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol. 2011;152(5):600-10. The only prospective study of high dose chemotherapy with ASCT in transformed lymphoma. PubMedCrossRef
37.
Hamadani M, Benson DM, Lin TS, Porcu P, Blum KA, Devine SM. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol. 2008;81(6):425–31.PubMedCrossRef
38.
Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P, et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant. 2007;13(8):956–64.PubMedCrossRef
39.
Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B, et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol. 2001;19(3):727–35.PubMed
40.
Villa KS D, Crump M, Toze C, Rubinger M, Lee C, Alzahrani M, et al. “Focus on…” session: high-dose chemotherapy. Ann Oncol. 2011;22 suppl 4:iv115–6.
41.
• Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M et al. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma. 2012;53(5):830-5. A retrospective analysis of ASCT in transformed lymphoma in patients previously exposed to rituximab. PubMedCrossRef
42.
Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ, et al. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant. 2008;42(9):601–8.PubMedCrossRef
43.
Ghesquières H, Berger F, Felman P, Callet-Bauchu E, Bryon P-A, Traverse-Glehen A, et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 2006;24(33):5234–41.PubMedCrossRef
44.
Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol. 2005;131(2):223–30.PubMedCrossRef
45.
Villa. Lugano ASCT transformed lymphoma. Ann Oncol. 2011;22(Supplement 4):iv10–24.CrossRef
46.
Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(2):211–7.PubMedCrossRef
47.
Clavert A, Le Gouill S, Brissot E, Dubruille V, Mahe B, Gastinne T, et al. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(8):1502–8.PubMedCrossRef
48.
Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P, et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant. 2009;15(5):547–53.PubMedCrossRef
49.
Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and maintenance improves progression free survival but not overall survival in patients with relapsed or resistant follicular lymphoma prior receiving an autologous transplant. ASH Annu Meet Abstr. 2010;116(21):3567.
50.
Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, et al. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol. 2011;154(4):477–81.PubMedCrossRef
51.
Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622–7.PubMedCrossRef
Metadata
Title
Transformation in Follicular Lymphoma: Biology, Prognosis, and Therapeutic Options
Authors
Eric Wong
Michael Dickinson
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 5/2012
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-012-0258-4

Other articles of this Issue 5/2012

Current Oncology Reports 5/2012 Go to the issue

Lymphomas (PA Hamlin, Section Editor)

NK/T-Cell Lymphomas: Pathobiology, Prognosis and Treatment Paradigm

Leukemia (A Aguayo, Section Editor)

Chronic Myeloid Leukemia: State of the Art in 2012

Leukemia (A Aguayo, Section Editor)

Diagnosis of Acute Leukemia in Cerebrospinal Fluid (CSF-Acute Leukemia)

Melanoma (K Margolin, Section Editor)

Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management

Lymphomas (PA Hamlin, Section Editor)

Active Immunotherapy: Current State of the Art in Vaccine Approaches for NHL

Lymphomas (PA Hamlin, Section Editor)

Novel Agents in Hodgkin Lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits